A Phase 1b/2, Randomised, Placebo-controlled Study to Evaluate Safety, Tolerability, Efficacy, and Immunogenicity of VTP-200, a Chimpanzee Adenovirus and Modified Vaccinia Ankara-vectored Multigenotype High-risk Human Papillomavirus Vaccine in Women With Low-grade Cervical Lesions
- 17 December 2025
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (1) , 51-58
Abstract
Background: The clearance of high-risk oncogenic human papillomaviruses (hrHPV) and related cervical lesions is associated with the development of a robust T-cell response. Therapeutic vaccination that induces HPV antigen-specific T cells is a promising approach. Method: A 2-vector dosing strategy using Chimpanzee Adenovirus Oxford 1-HPV and Modified Vaccinia virus Ankara-HPV, both encoding the same multiantigen HPV cassette was given on a 0/28-day schedule to participants with persistent cervical hrHPV and a history of low-grade cervical lesions. An open-label lead-in was followed by a randomized, blinded, placebo-controlled main phase. The primary endpoint was the safety of the different dose regimens; secondary endpoints included immunogenicity, and clearance of hrHPV and associated lesions at 12 months. Nine participants were enrolled in the lead-in and 99 were randomized 67:32 to 5 active dose arms or placebo, respectively. Results: The regimens were well-tolerated with no grade 3–related treatment emergent adverse events or serious adverse reactions. All dosing regimens generated antigen-specific CD4+ and CD8+ T-cell responses. There was no difference in hrHPV clearance between the pooled active groups and placebo (20/64 [31.3%] versus 10/30 [33.3%]; P > .99), nor in lesion clearance. A trend toward higher hrHPV clearance (60%) was observed with the highest Chimpanzee Adenovirus Oxford 1-HPV doses. No association between the peripheral immune response and clearance was demonstrated. Conclusions: A heterologous, multiantigenic HPV 2-component immunotherapy regimen was well-tolerated and immunogenic but did not result in a statistically significant clearance of either hrHPV or the associated cervical lesions in women with persistent high-risk HPV infections. Trial registration: EudraCT 2019-001890-98; NCT04607850Keywords
Funding Information
- Barinthus Biotherapeutics
This publication has 38 references indexed in Scilit:
- Comparison of four assays for human papillomavirus detection in the anal canalClinical Microbiology and Infection, 2022
- Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study)eClinicalMedicine, 2019
- Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adultsJournal of Infection, 2019
- Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy AdultsEBioMedicine, 2018
- Adenovirus vector‐based prime‐boost vaccination via heterologous routes induces cervicovaginal CD8+ T cell responses against HPV16 oncoproteinsInternational Journal of Cancer, 2017
- CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trendCancer Immunology, Immunotherapy, 2011
- Therapeutic HPV DNA vaccinesImmunologic Research, 2010
- A prospective study on the natural course of low‐grade squamous intraepithelial lesions and the presence of HPV16 E2‐, E6‐ and E7‐specific T‐cell responsesInternational Journal of Cancer, 2009
- Effect of Human Papillomavirus 16/18 L1 Viruslike Particle Vaccine Among Young Women With Preexisting InfectionJAMA, 2007
- Differential Distribution of Sequence Variations in HPV-16 E6Gynecologic Oncology, 2000